戻る Agenda
Opportunities and Challenges of Collecting Data in a Pre-Approval Access Setting: A Multi-Stakeholder Perspective
Session Chair(s)
Beverly L Harrison
Head, Patient Support
Janssen Pharmaceutical Companies of Johnson & Johnson, United States
This session reviews the benefits and risks of collecting real world data through single-patient requests (SPRs)/expanded access programs (EAPs) in a pre-approval access (PAA) setting and discusses what may confer the highest value to an organization from a multi-stakeholder perspective.
Learning Objective : Recognize relevance and value for an organization of collecting real world data: Discuss the value of real world data from a pre-approval access (PAA) setting as it relates to regulatory and access strategies; Describe benefits and risks of collecting real world data in an single-patient requests (SPR)/named-patient program (NPP) and its potential implications on regulatory and access strategies.
Speaker(s)
Pre-Approval Access and Real World Evidence Landscape Set-up
Sasha Richardson, MBA, MSC
EY, United States
Managing Director
Panelist
Arnaud Foucher, MBA, MS
Janssen, France
EMEA Medical Program Director, Medical Affairs, Europe, Middle-East and Africa
Panelist
Alison Bateman-House, PHD, MA, MPH
NYU Grossman School of Medicine, United States
Assistant Professor, Division of Medical Ethics, Dept of Population Health
Panelist
Michael Fine, MD
Health Net, United States
Medical Director